Patents by Inventor Laurens Adrianus Hendricus van Pinxteren

Laurens Adrianus Hendricus van Pinxteren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Rabeximod compounds
    Patent number: 11643415
    Abstract: Rabeximod compounds selected from HCl salts, methane sulphonic acid salts and malonic acid salts of Rabeximod. Also, a pharmaceutical composition including a Rabeximod compound, and optionally a pharmaceutically acceptable additive. Further, a method for treatment of a mammal, such as a human subject, suffering from or diagnosed with rheumatoid arthritis, preferably moderate rheumatoid arthritis, severe rheumatoid arthritis or moderate to severe rheumatoid arthritis. The method includes administering to the mammal subject an amount of a Rabeximod compound effective to treat the rheumatoid arthritis.
    Type: Grant
    Filed: August 19, 2022
    Date of Patent: May 9, 2023
    Assignee: CYXONE AB
    Inventors: William Dalby Brown, Laurens Adrianus Hendricus Van Pinxteren, Rienk Elibert Steendam, Jonathan Knibbe, Malin Ingrid Berthold
  • miRNA-193a for Promoting Immunogenic Cell Death
    Publication number: 20230136088
    Abstract: The invention relates to the use of miRNA-193a for regulating gene expression, particularly it relates to the use of miRNA-193a as a CRT agonist, promoting the cell surface expression of CRT. This allows the advantageous treatment of cancers without or with low surface expression of CRT. The invention further relates to compositions comprising the miRNA for use in such treatment.
    Type: Application
    Filed: February 26, 2021
    Publication date: May 4, 2023
    Applicant: INTERNA TECHNOLOGIES B.V.
    Inventors: Sanaz YAHYANEJAD, Bryony TELFORD, Marion VAN DEN BOSCH, Mir Farshid ALEMDEHY, Matheus Maria DE GUNST, Laurens Adrianus Hendricus VAN PINXTEREN, Roeland Quirinus Jozef SCHAAPVELD, Michel JANICOT
  • NEW TREATMENTS INVOLVING MIRNA-193A
    Publication number: 20220275368
    Abstract: The invention relates to the use of miRNA-193a for regulating gene expression, particularly it relates to the use of miRNA-193a as a PTEN agonist. This allows the advantageous treatment of PTEN-deficient cancers. The invention further relates to compositions comprising the miRNA for use as a PTEN agonist.
    Type: Application
    Filed: March 6, 2020
    Publication date: September 1, 2022
    Applicant: INTERNA TECHNOLOGIES B.V.
    Inventors: Sanaz YAHYANEJAD, Bryony Jane TELFORD, Marion Tina Jolien VAN DEN BOSCH, Mir Farshid ALEMDEHY, Matheus Maria DE GUNST, Laurens Adrianus Hendricus VAN PINXTEREN, Roeland Quirinus Jozef SCHAAPVELD, Michel JANICOT
  • ANTICANCER MICRORNA AND LIPID FORMULATIONS THEREOF
    Publication number: 20210038732
    Abstract: The present invention relates to a lipid formulation comprising microRNA. The formulation comprises cationic lipids that can form lipid nanoparticles with the microRNA. The formulations are useful in medicine.
    Type: Application
    Filed: February 12, 2019
    Publication date: February 11, 2021
    Applicant: INTERNA TECHNOLOGIES B.V.
    Inventors: Matheus Maria DE GUNST, Laurens Adrianus Hendricus VAN PINXTEREN, Michel JANICOT, Iman Johannes SCHULTZ, Roeland Quirinus Jozef SCHAAPVELD, Sanaz YAHYANEJAD
  • POWDER FORMULATION
    Publication number: 20190269764
    Abstract: The invention relates to sterile powder compositions suitable for medical use comprising thrombin and fibrinogen, and to methods for producing the same, wherein the thrombin powder is produced from a liquid feedstock, wherein the feedstock comprises a solution or a suspension of thrombin, preferably a solution, wherein the powder is produced by removal of liquid by a process selected from aseptic spray drying or aseptic fluid bed drying, and wherein the powder resulting from removal of liquid from the feedstock exhibits at least 80% of the thrombin potency or activity of the liquid feedstock, and wherein the fibrinogen powder is produced by removal of liquid from a feedstock, wherein the feedstock comprises a solution or a suspension of fibrinogen, preferably a solution, by aseptic spray drying or aseptic fluid bed drying, and wherein said composition is packaged as a sterile final pharmaceutical product for medical use.
    Type: Application
    Filed: May 10, 2019
    Publication date: September 5, 2019
    Inventors: Laurens Adrianus Hendricus van Pinxteren, Glen Martyn, Nicola Kim Whitfield
  • POWDER FORMULATION COMPRISING THROMBIN AND FIBRINOGEN
    Publication number: 20160015792
    Abstract: The invention relates to sterile powder compositions suitable for medical use comprising thrombin and fibrinogen, and to methods for producing the same, wherein the thrombin powder is produced from a liquid feedstock, wherein the feedstock comprises a solution or a suspension of thrombin, preferably a solution, wherein the powder is produced by removal of liquid by a process selected from aseptic spray drying or aseptic fluid bed drying, and wherein the powder resulting from removal of liquid from the feedstock exhibits at least 80% of the thrombin potency or activity of the liquid feedstock, and wherein the fibrinogen powder is produced by removal of liquid from a feedstock, wherein the feedstock comprises a solution or a suspension of fibrinogen, preferably a solution, by aseptic spray drying or aseptic fluid bed drying, and wherein said composition is packaged as a sterile final pharmaceutical product for medical use.
    Type: Application
    Filed: March 7, 2014
    Publication date: January 21, 2016
    Inventors: Laurens Adrianus Hendricus van Pinxteren, Glen Martyn, Nicola Kim Whitfield